Cabaletta Bio Inc (CABA) Unusual Options Activity Today

Checking CABA unusual options activity helps you spot when traders are making outsized bets on Cabaletta Bio Inc before the broader market catches on. Cabaletta Bio Inc's unusual options activity flags contracts trading at multiples of their average daily volume, often signaling that informed money is positioning ahead of a catalyst. Use our scanner to monitor CABA unusual options activity today and surface the prints that deserve a second look.

Unusual options flow typically refers to trades where volume vastly exceeds open interest at a given strike, or where total contract volume on a name spikes well above its norm. Watching CABA unusual options flow today can reveal large block trades, sweeps across exchanges, and aggressive directional bets. Tracking CABA unusual options volume across calls and puts helps you separate hedging activity from genuinely speculative positioning, and CABA unusual options flow data becomes especially valuable around earnings, product launches, and macro events.

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.

Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Catalysts rarely arrive without a footprint, and CABA unusual options activity is often where that footprint shows up first. Our scanner tracks Cabaletta Bio Inc's unusual options flow in real time, ranks prints by volume-to-open-interest, premium spent, and aggressor side, and separates real conviction from noise. Whether you're looking at CABA unusual options volume on the call side or chasing put sweeps, Cabaletta Bio Inc's unusual options flow today is one click away, so put it on your radar before the headlines hit.